CD47 and pancreatic ductal adenocarcinoma: Cioffi and colleagues tested the effect of inhibiting CD47 in pancreatic ductal adenocarcinoma (PDAC) and reported that while anti-CD47 antibodies increased phagocytosis in vitro, it did not result in a statistically significant change in tumor growth in a PDAC patient-derived xenograft (PDX) model unless administered in combination with a chemotherapeutic agent (Cioffi et al., 2015).